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Abstract As part of our exploration for new antifungal agents, substituted 4,5-diphenyl imidazolyl
pyrimidine hybrids were synthesized. A series of substituted ethyl 1,2,3,6-tetrahydro-4-methyl-2-
oxo/thioxo-6-phenyl-1-(4,5-diphenyl-1-H-imidazol-2-yl) pyrimidine-5-carboxylates have been stud-
ied for their binding active sites of cytochrome P450 14a-sterol demethylase CPY51 enzyme. For
comparison, the binding behavior of known 14DM selective (Fluconazole) and non-selective
(Clotrimazole, Miconazole, Griesofulvin) drugs has also been studied. Synthesized compounds were
screened for their in vitro antibacterial activity against Staphylococcus aureus, Salmonella typhi,
Pseudomonas aurogenosa and Klebsiella pneumonae and also antifungal activity against the oppor-
tunistic pathogens Candida albicans.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Candida albicans, the most prevalent opportunistic fungal
pathogen in humans, has been part of a general increase in
the number of infection i.e. Candidiasis (Staib, 1965, 1969)
ranging from superﬁcial mucosal infection to life-threatening
systemic diseases in immuno compromised patients (with
AIDS, Cancer, or Organ transplant). Azole compounds pos-
sessing N–C–N grouping display anti-inﬂammatory (Krimmel,
1961; Chem. Abstr., 1961a,b), hypotensive, anti-convulsant
(Chem. Abstr., 1961a,b), amebicidal activity (Butter et al.,
1967). The search for better antibacterial and antifungal agents
with increased speciﬁcity towards bacterial as well as fungal
enzymes remains a primary target in medicinal chemistry re-
search. Many azoles target lanosterol 14 a-sterol demethylase
and block ergosterol synthesis by interfering with the demeth-
ylation of its precursor (Fig. 1). Their broad therapeutic
window, wide spectrum of activity and low toxicity has stimu-
lated interest and revealed additional antimycobacterial activ-
ity associated with antifungal activity (Fioraventi et al.,
1997a,b; Bobbarala and Naidu, 2009; Zhang et al., 2010).
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We thought it desirable to undertake the synthesis and bio-
assay of compounds incorporating pyrimidine nucleus along
with imidazole moiety in the same molecular framework to im-
prove its speciﬁcity and efﬁcacy against the microorganisms.
Microwave (MW) irradiation (Singh et al., 2010) is currently
used to carry out a wide range of reactions in short reaction
time, with high productivity and stereo selectivity (Sharma
and Mishra, 2010). We aimed to perform organic reactions un-
der solvent free dry media conditions that avoid use of toxic
solvents, thus preventing pollution (Melagraki et al., 2006).
Microwave induced synthesis of the differently substituted
ethyl 1,2,3,6-tetrahydro-4-methyl-2-oxo/thioxo-6-phenyl-
1-(4,5-diphenyl-1-H-imidazol-2-yl) pyrimidine-5-carboxylate
3a–g using acidic alumina has advantages over traditional
methods. The dry media reaction proceeded rapidly in a for-
ward direction and the time required for completion was
highly reduced from hours to minutes.
The recent renewed interest in various imidazole analogues
prompted the present study to demonstrate the use of synthesis
and the utility of docking techniques has successfully veriﬁed
for biological evaluation. Thus the application of newly syn-
thesized derivatives saved time and human resource consider-
ably. It is noteworthy to mention that this work provides
a lead molecule, which can be further explored on the basis
of present results to enhance the potential efﬁcacy of
pharmacophores.
2. Experimental
2.1. Chemistry
Differently substituted formylpyrimidines were made using
analytical grade benzaldehyde, chlorobenzaldehyde, anisalde-
hyde, nitrobenzaldehyde (S.D. Fine Chem. 98%), Urea/thio-
urea, Absolute alcohol (99%), H2SO4 (Fischer 98%), DMF
and POCl3 (Thomas baker, 98%), Benzil (S.D. Fine Chem.
98%), Ammonium acetate and Glacial acetic acid (S.D. Fine
Chem. 98%).
All solvents were distilled prior to use. TLC was performed
on silica gel G. Melting points were determined by open capil-
lary method and are uncorrected. IFB Domestic Microwave
was used. 1HNMR and 13CNMR spectra were recorded from
CDCl3/DMSO-d6 solution on a Brucker Avance II 400
(400 MHz) NMR Spectrometer. Chemical shifts are reported
in ppm using TMS as an internal standard. IR spectra were
obtained on a Shimadzu FTIR spectrophotometer using KBr
discs. Mass spectra were recorded by using Shimadzu gas chro-
matograph coupled with QP5050 Spectrometer at 1–1.5 ev.
X-ray diffraction analysis was carried out with FR590
MACH3 Single Crystal diffractometer. All the structures were
resolved by direct methods using the solution program9
SHELX-97 in the WinGX package.
2.2. General procedure for synthesis of substituted ethyl 1,2,3,6-
tetrahydro-4-methyl-2-oxo/thioxo-6-phenyl-1-(4,5-diphenyl-1-
H-imidazol-2-yl) pyrimidine-5-carboxylates 3a–g
2.2.1. Conventional method
Substituted ethyl 1-formyl-1,2,3,6-tetrahydro-4-methyl-6-phe-
nyl-2-oxo/thioxopyrimidine-5-carboxylates 1a–g (25 mmol),
Benzil 2 (25 mmol, 5.25 g) and ammonium acetate (10 g) were
dissolved in glacial acetic acid and reﬂuxed for 10–12 h. After
reﬂuxing, the reaction mixture was left overnight and ﬁltered
to remove any precipitate. Water (300 mL) was then added
to the ﬁltrate and the ﬁrst crop of crude material was obtained.
The ﬁltrate was neutralized with ammonium hydroxide and a
second crop of the solid was collected. The two crops of the
precipitate were combined, dried and recrystallized from
ethanol.
2.2.2. Microwave irradiation method
Substituted ethyl 1-formyl-1,2,3,6-tetrahydro-4-methyl-6-phe-
nyl-2-oxo/thioxopyrimidine-5-carboxylates 1a–g (25 mmol),
Benzil 2 (25 mmol, 5.25 g), ammonium acetate (10 g) and
acidic alumina (1.0 g) were mixed thoroughly in an agate
mortar. The mixture was placed in a beaker, 2-drops of glacial
acetic acid was added. The beaker was kept in a microwave
oven at maximum power level for 8 min with intermittent
interval. The progress of reaction was monitored by TLC using
benzene:ethyl acetate (8:2). The dried mass was diluted in cold
water to dissolve acidic alumina and crude product was recov-
ered, washed with ammonium hydroxide. The obtained mass
was dried and recrystallized from ethanol (Scheme 1).
2.3. Computational evaluation: docking study
2.3.1. Methodology
All molecular techniques used in this manuscript were per-
formed on Argus Lab ver. 4.0-work system. The starting 3D
structure (Boscott and Grant, 1994) of the cytochrome
P450sterol 14DM CPY51 of C. albicans was downloaded from
the Protein Data Bank (http://www.rcsb.org) as PDB ﬁles
(PDB entry: 1ea1).
2.3.2. 1ea1
The ﬁle containing the crystal structure of cytochrome
P450a-sterol demethylase (14DM) with its selective inhibitor
i.e. Fluconazole (470TPF) in the active site (PDB entry 1ea1,
six ligand) was downloaded. It is monomer structure with only
chain A consisting of 449 residues. This chain A has 470YPF,
water and 1 heme (HEM) groups. The chain A with residues,
water and the hetero groups (HEM) within a radius of 5 A˚ was
Figure 1 Mechanism of azoles drugs in biosynthesis pathway.
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reﬁned and cleaned by checking the hybridization, valence of
the ligand and introducing H-atoms to the protein residues.
1ea1 carries net charge 2 and 3590 atoms. The active sites of
residues of 1ea1 are shown in (Fig. 2).
2.3.3. Docking and binding evaluation
In the automated module of Argus Lab ver. 4.0 work systems,
the ligand was docked into the active site of cytochrome P450
14a-sterol demethylase (14DM) from C. albicans using Argus
dock with a fast, simpliﬁed potential of mean force (PMF).
The docking is carried with ﬂexible ligand into a rigid protein
active site. The general procedure for docking process starts
with the addition of energy minimized target ligand on the
enzyme. The active site and the ligand were speciﬁed in the
program. The different starting parameters were optimized
by using 15 · 15 · 15 box located at the centre of the target
active site using a united atom (explicit hydrogen are not con-
sidered) potential of mean force (PMF) with a docking algo-
rithm that has a population of 50 chromosomes and runs for
6000 generations. The process of docking is repeated until a
constant value of docking score is reached. This takes about
12,000–18,000 generation. The ﬁnal results are parameterized
in terms of docking score in kcal/mol. The docked ligand–
P450 (14DM) CPY51 complex is interpreted by looking at
the H-bonding or hydrophobic interaction of the ligand with
the amino acid residues in the active site. The same procedure
was followed for docking of different substituted 4,5-imidazo-
lyl pyrimidine into the active site of cytochrome P450 14a-ste-
rol demethylase CPY51 enzymes.
2.3.4. Validation of PMF method
To ensure the validation of the programme, before docking the
test compounds, the docking of Fluconazole (470TPF) into the
active site of P450 14DM was performed. This selective inhib-
itor of cytochrome P450 binds in the active site with a binding
score of 9.1128 cal/mol. The docked structure of Fluconazole
in the active site of cytochrome P450 is shown in (Fig. 2).
2.3.5. Docking of known selective and non-selective cytochrome
P450 demethylase inhibitors into the active site of 1ea1
The non-selective behavior of Clotrimazole, Miconazole,
Griesofulvin and selective behavior of Fluconazole towards
cytochrome P450 (14DM) CY51 is in reasonable agreement
with their binding energy (docking score) with 1ea1 as calcu-
lated from the docking of these compounds in 1ea1 active site.
During binding of this known antifungal drug in the binding
pocket of cytochrome P450, the conformational placement of
amino acid residues in the active site is observed.
2.3.6. Docking of imidazolylpyrimidine derivatives into active
site of 1ea1
The docking of synthesized substituted 4,5-diphenyl imidazolyl
pyrimidine derivatives (Scheme 1) 3a–g in 14DM active site
has been studied.
Scheme 1
Figure 2 Active site residues of cytochrome P450 (14DM)
CPY51 with Fluconazole (470TPF) hydrogens are suppressed for
clarity.
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2.4. Biology
2.4.1. In vitro antibacterial activity
As the sensitivity was not observed at conc. <100 lg disc1,
the antibacterial activity of compounds 3a–g has been assayed
at concentration of 100 lg disc1 against strains of Gram +ve
and Gram ve pathogenic bacteria (Salmonella typhi, Pseudo-
monas aurogenosa, Klebsiella pneumonae and Staphylococcus
aureus). Initially, susceptibility testing was carried out by mea-
suring the inhibitory zone diameter on Muller–Hinton agar,
with conventional paper disc diffusion method (Fioraventi
et al., 1997a,b), and the inhibitory zone diameters were read
and rounded off to the nearest whole numbers (mm) for anal-
ysis. The inhibitory effects of compounds 3a–g against these
organisms were compared with standard drug i.e. Norﬂoxacin.
2.4.2. In vitro antifungal activity
As the sensitivity was not observed at conc. <100 lg disc1,
the antifungal activities of compounds 3a–g have been assayed
in vitro at a concentration 100 lg disc1 against C. albicans.
Griesofulvin was used as standard fungicide for the antifungal
test. Muller–Hinton agar was used as basal medium for test
fungi (Fioraventi et al., 1997a,b). Glass Petri dishes were ster-
ilized and 10 ml of sterilized melted MH agar medium (45 C)
was poured into each Petri dish. After solidiﬁcation of the
medium, small portion of mycelium of C. albicans was spread
carefully over the centre of each MH agar plate with the help
of spreader. Thus, fungus was transferred to each plate. The
plates were then incubated at (27 C) and after half an hour
of incubation they were ready for use. The prepared discs of
test sample were placed gently with sterile forceps on the solid-
iﬁed agar plate, freshly seeded with the test organisms. The
plates were then incubated at 37.5 C for 24 h. Dimethyl form-
amide (DMF) was used as a solvent to prepare desired solu-
tions of the compounds initially.
3. Results and discussion
3.1. Chemistry
Substituted ethyl 1,2,3,6-tetrahydro-4-methyl-2-oxo/thioxo-
6-phenyl-1-(4,5-diphenyl-1-H-imidazol-2-yl) pyrimidine-5-car-
Table 1 Characteristic spectral data of synthesized compounds 3a–g.
Entry m.p. (C) IR (cm1) Chemical shifts (dH) in
ppm
Chemical shifts (dC) in
ppm
Yield (%) Molecular formula Mass [M+]
MW Conv.
3a 160 3198 (N–H), 1499
(C‚C), 1435 (C‚N)
1.1 (t, 3H, CH3, J= 8),
2.3 (s, 3H, CH3), 4.2 (q,
2H, CH2, J= 4.8), 5.1
(s, 1H, Ar–H), 8.9 (s, 1H,
N–H)
13.7, 17.7, 54.4, 59.0,
99.7, 127.2, 128.6, 129.5,
129.3, 132.7, 134.2,
147.1, 148.2, 158.8,
165.3, 167.1, 194.1
79 64 C2H26N4O3 478
3b 210 3190 (N–H), 1493
(C‚C), 1430 (C‚N)
1.3 (t, 3H, CH3, J= 8),
2.1 (s, 3H, CH3), 4.1 (q,
2H, CH2, J= 4.8), 5.4
(s, 1H, Ar–H), 8.7 (s, 1H,
N–H)
13.5, 17.9, 54.2, 59.0,
99.6, 127.1, 128.6, 129.5,
129.3, 132.3, 134.0,
147.8, 148.5, 158.8,
165.7, 167.1, 194.3
78 64 C29H25N4O3Cl 523
3c 180 3198 (N–H), 1549
(C‚C), 1435 (C‚N)
1.4 (t, 3H, CH3,
J= 7.6), 2.4 (s, 3H,
CH3), 4.0 (q, 2H, CH2,
J= 4.2), 5.2 (s, 1H, Ar–
H), 9.2 (s, 1H, N–H)
13.4, 17.6, 54.3, 59.2,
99.7, 127.2, 128.4, 129.5,
129.6, 132.7, 134.6,
147.1, 148.2, 158.53,
167.1, 194.8
69 62 C29H25N5O5 512
3d 240 3195 (N–H), 1489
(C‚C), 1469 (C‚N)
1.1 (t, 3H, CH3,
J= 8.2), 2.3 (s, 3H,
CH3), 3.7 (s, 3H, OCH3),
4.0 (q, 2H, CH2,
J= 4.8), 5.3 (s, 1H, Ar–
H),
8.9 (s, 1H, N–H)
13.2 17.6, 54.1, 59.3,
99.7, 127.2, 128.6, 129.5,
129.3, 132.7, 134.1,
147.1, 148.2, 158.8,
165.3, 167.1, 194.5
72 65 C30H28N4O4 508
3e 190 3198 (N–H), 1494
(C‚C), 1430 (C‚N)
1.3 (t, 3H, CH3, J= 8),
2.2 (s, 3H, CH3), 4.2 (q,
2H, CH2, J= 4.8), 5.5
(s, 1H, Ar–H), 9.5 (s, 1H,
N–H)
13.3, 17.7, 54.4, 59.0,
99.2, 127.4, 128.6, 129.5,
129.3, 132.7, 134.2,
147.1, 148.2, 158.8,
165.3, 167.1, 194.3
78 65 C29H26N4O2S 494
3f 195 3200 (N–H), 1493
(C‚C), 1433 (C‚N)
1.2 (t, 3H, CH3, J= 8),
2.4 (s, 3H, CH3), 4.1 (q,
2H, CH2, J= 4.8), 5.3
(s, 1H, Ar–H), 9.3 (s, 1H,
N–H)
13.7, 17.7, 54.4, 59.3,
99.7, 127.2, 128.6, 129.5,
129.3, 132.7, 134.0,
147.1, 148.2, 158.8,
165.3, 167.1, 194.4
75 63 C29H25N4O2SCl 528
3g 220 3205 (N–H), 1495
(C‚C), 1435 (C‚N)
1.3 (t, 3H, CH3, J= 8),
2.3 (s, 3H, CH3), 4.0 (q,
2H, CH2, J= 4.6), 5.1
(s, 1H, Ar–H), 9.6 (s, 1H,
N–H)
13.4, 17.6, 54.4, 59.0,
99.3, 127.2, 128.6, 129.5,
129.3, 132.7, 134.0,
147.1, 148.2, 158.8,
165.3, 167.1, 194.7
67 60 C29H25N5O4S 539
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boxylates 3a–g were synthesized by conventional and
non-conventional methods. Condensation of substituted ethyl
1-formyl-1,2,3,6-tetrahydro-4-methyl-6-phenyl-2-oxo/thioxo-
pyrimidine-5-carboxylate 1a–g and Benzil 2 using acidic alu-
mina and ammonium acetate under solvent free microwave
irradiation was adopted preferentially as it was an environ-
mentally friendly and economically proﬁtable method that re-
duced the time of reaction from hours to minutes (Table 1).
The structure of ethyl 1,2,3,6-tetrahydro-4-methyl-2-oxo-6-
phenyl-1-(4,5-diphenyl-1-H-imidazol-2-yl) pyrimidine-5-car-
boxylate 3a was supported by elemental analysis, IR, 1HNMR,
13CNMR, MASS spectral data. IR spectra exhibited an N–H
absorption band at 3198 cm1, ester carbonyl group at
1750 cm1, C‚C stretch at 1495 cm1, C‚N stretch at
1435 cm1. 1HNMR (CDCl3/DMSOd6) was nicely resolved
and showed the appearance of N–H proton as a characteristic
singlet at d 8.9 and the aromatic protons as a multiplet at d7.1–
7.9 (Table 1). The appearance of multiplets of 14 protons at d
7.2–8.5 showed the presence of two more phenyl rings attached
to the basic moiety; the disappearance of the –CHO peak from
d 10.2–10.4 conﬁrmed the formation of product 3a. 13CNMR
showed the disappearance of peak of H–C‚O in compound
3a; the appearance of peak of N–C–N at d 134.0 conﬁrmed
its structure.
The construction of the imidazole ring on N-formylpyrimi-
dine 3a–g was performed in a facile manner affording the ﬁnal
compounds in overall good yield with high purity. A simple
Table 2 Crystal and experimental data for the title
compound.
Chemical formula C29H26N4O3
Molecular weight (g/mol) 478
Crystal size 0.2 · 0.24 · 0.05
Crystal system Triclinic
Space group P
Unit cell dimensions
a 4.1532
b 4.518
c 5.25
a 76
b 88
c 104
Volume 98.507
(Cal.) Density (g/cm3) 0.206
F (000) 252
Index range (h, k, l) h (0-5), k (0-5), l (0-4)
Absorption correction Integration
Absorption coeﬃcient 0.053
Goodness of ﬁt on F2 0.98
Final R indices [I> 2r (I)] 0.03
Temperature 299 K
Radiation Mo Ka
k 0.70930
R 0.0394
Rw 0.0828
Figure 3 An ORTEP drawing of the molecule 3a showing the atomic numbering system.
Figure 4 Active site residues of cytochrome P450 (14DM)
CPY51 with clotrimazole hydrogens are suppressed for clarity.
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strategy was developed for the synthesis of 4,5-diphenyl imi-
dazolylpyrimidine derivatives 3a–g in which the two aryl rings
are placed at C-4 and C-5 carbon on the opposite faces of the
nearly planar imidazole ring. The structural arrangement and
characterization of compound 3a was proved by X-ray crystal
analysis.
3.1.1. A-single crystal XRD 3a
Yellow coloured needle shape single crystals suitable for X-ray
diffraction were grown from methanol using the slow evapora-
tion technique. Diffraction intensity data were collected with a
FR590 MACH3 single crystal diffractometer using Mo Ka
monochromated radiation (k= 0.70930) at room temperature
(299 K). Crystal data, data collection and structure reﬁnement
for the compound are listed in (Table 2). The ﬁnal atomic
coordinates for all atoms and a complete listing of bond dis-
tance and angles are tabulated.
An integration type of absorption correction was applied to
data sets. The structure was resolved by direct methods using
the solution program SHELXS97 in the WinGX package
(Sheldrick, 1997) and reﬁned by a full-matrix least-squares
procedure on F2 using SHELXS97. All non-hydrogen atoms
were reﬁned, ﬁrst with isotropic and then anisotropic parame-
ters. Hydrogen atoms bonded to carbon were included using a
riding model, starting from calculated positions. An ORTEP-3
(Farrugia, 1997) drawing of the molecule with the atomic num-
bering scheme is shown in (Fig. 3).
3.2. Docking study
Clotrimazole binds in the active site of cytochrome P450 (1ea1)
mainly through hydrophobic interaction. Clotrimazole mainly
has two phenyl ring attached to the same carbon atom. Phenyl
ring (C) is surrounded by VAL 434, HIS 59, PHE 255, and
ALA 256; phenyl ring (D) is enveloped by TYR 76 and
LEU 321 (Fig. 4). It also contains one p-chloro substituted
phenyl ring which approaches PHE 78, MET 79, PHE 83,
and ARG 96. Therefore –Cl substituted phenyl ring present
on Clotrimazole through p–p interaction with amino acid res-
idues kept in place in active site of cytochrome P450, increases
the binding energy, by 15.4404 kcal/mol (Table 3).
These compounds contain a central core imidazole ring
having N–C–N bonding, characteristic of azole antifungal
drugs. Two aryl rings at C-4 and C-5 carbon on the opposite
faces of two nearly planar imidazole ring result in decrease
in steric repulsion on the opposite faces of the imidazole ring
providing for free rotation of the two aryl rings. All the synthe-
sized imidazolyl pyrimidine molecules show binding in the ac-
tive site of P450 (14DM) CPY51 with binding score between
7.86 and 12.45 kcal/mol (Table 3). Compounds 3a, 3b,
3c, 3d, 3f show the highest binding with P450 (14DM) in
comparison to selective drug i.e. Fluconazole. Further ratio-
nalization of modes of P450 (14DM) CPY51 has been based
upon the amino acid residues present around the ligand, in
the active site pocket of 1ea1. On the basis of structural fea-
tures essential for binding in the cavity, the imidazolyl pyrim-
idine molecules could be divided into three segments: C-4
phenyl, C-5 phenyl, C-2 substituted pyrimidine. The residues
surrounding each phenyl group and C-2 substituted pyrimidine
molecules have been determined (Table 4).
Table 3 Binding score of known selective and non-selective
drugs and 4,5-diphenyl imidazolylpyrimidine derivatives
(DPIP) with P450 (14DM) CPY51.
Entry Ligand Binding score (Kcal/mol)
1 Clotrimazole(non-selective) 15.4404
2 Miconazole(non-selective) 12.9387
3 Griesofulvin(non-selective) 9.2418
4 Fluconazole(selective) 9.1128
5 3a 11.98
6 3b 12.4528
7 3c 12.2386
8 3d 11.98
9 3e 9.9351
10 3f 12.0495
11 3g 7.8615
Table 4 Amino acid residues around each segment of imidazolylpyrimidine derivatives docked into cytochrome P450 (14DM)
CPY51.
Entry Ligand Amino acid residues surrounding
C-2 substituted pyrimidine ring C-4 phenyl ring C-5 phenyl ring
1 3a ALA 397, ILE 401, LEU
315,LYS 312, GLU 308
PHE 387, ARG 393, ALA 389,
GLY 388
ARG 381, ASN 380, LEU 378, ASP 377, TRP 384
2 3b GLY 388, ILE 385, ARG 393,
TRP 384, AR 381, ASN 380,
PRO 386
LEU 315, LYS 312, LEU 311,
PHE 387
ILE 401, GLU 308, LEU 378, ASP 377
3 3c MET 253, LEU 152, GLU 98,
GLU 94
PHE 89 LEU 229, VAL 228, MET 225, MET 249
4 3d GLU 308, ALA 397, ALA 398,
ILE 401
ASP 377, LEU 378, LYS 312 TRP 384, LEU 315, PHE 387, ARG 393
5 3e ALA 350, ILE 27, ILE 351, ASP
25, GLY 28, GLN 31, ARG 354
ASN 428, HIS 430, ILE 322 HIS 318, TRP 267, LEU 317, HIS 363
6 3f GLU 308, LEU 311, LYS 312,
ILE 401, LEU 315, ALA 397,
ALA 398
PRO 386, ARG 393, ILE 385,
PHE 387, GLY 388
TRP 384, LEU 378, ASP 377, ARG 381, ASN 380
7 3g LYS 233, VAL 232, ALA 23,
PHE 241, VAL 88, PHE 89
ARG 223 LEU 229, VAL 228
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The most prominent binding is observed in ligands 3b, 3c
and 3f as compared to their other substituent. For ligands 3b
and 3f, the two phenyl rings are stabilized by hydrophobic
interaction. In case of 3b, C-4 phenyl ring is surrounded by
LEU 315, LEU 311, LYS 312 and PHE 387. C-5 phenyl ring
is surrounded by LEU 378, ILE 401, GLU 308, ASP 377
and C-2 substituted pyrimidine is enveloped by GLY 388,
ILE 385, ARG 393, TRP 384, ARG 381, ASN 380, PRO
386 (Fig. 5). In 3f, C-4 phenyl ring is surrounded by PRO
386, ARG 393, ILE 385, PHE 387 and GLY 388. The C-5 phe-
nyl ring is surrounded by TRP 384, LEU 378, ASP 381, ASN
380; the C-2 substituted pyrimidine molecule is surrounded by
GLU 308, LEU 311, LYS 312, ILE 401, LEU 315, ALA 397,
ALA 398 (Fig. 6). These C-2 substituted pyrimidine have hal-
ogen –Cl atom as a substituent of phenyl ring: in compound 3b
and 3f the binding score is increased by 12.4528 and
Figure 5 Docked in the active site of cytochrome P450 3b.
Figure 6 Docked in the active site of cytochrome P450 3f.
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12.0495 kcal/mol respectively through p–p interaction with
amino acid residues kept in active site of cytochrome P450.
For ligand 3c, C-4 phenyl ring approaches PHE 89. C-5 phenyl
ring is surrounded by LEU 229, VAL 228, MET 225, MET
249, GLU 98. The C-2 substituted pyrimidine having NO2 as
substituent of phenyl ring are surrounded by MET 253,
LEU 152, GLU 94: the docking score is 12.2386 kcal/mol
(Fig. 7).
3.3. Biology
3.3.1. In vitro antibacterial and antifungal activities
The screening results revealed that in addition to 3a–c, the
compound 3d was found to be the most active against S. aur-
eus amongst all the tested compounds. S. typhi is highly sensi-
tive to the compound 3b and 3e–g while moderately sensitive
to Compounds 3a and 3c. The results depicted in Table 5 sug-
gested that P. aurogenosa and K. pneumonae are highly resis-
tant to the synthesized compounds. In vitro antifungal
studies revealed that the compounds 3b and 3c displayed sig-
niﬁcant activity while rest of the compounds showed moderate
to low activity (Table 5).
Similarly preliminary studies in order to verify how the syn-
thesized azole compounds interact at the target enzyme cyto-
chrome P450-dependent lanosterol 14a-demethylase (P450
14DM, CPY51) in the ergosterol biosynthesis pathway have
been carried out by computational approach and structure–
activity relationship.
3.3.2. Structure–activity relationship
A comparative study involving the interaction of known anti-
microbial drug viz. Clotrimazole, Miconazole, Fluconazole,
and Griesofulvin in the active site pocket of cytochrome
P450 (1ea1) was made for better understanding of their anti-
bacterial and antifungal action. Structure–activity relation-
ship, a powerful stencil used for tailoring effective lead
molecules, was studied. We tested the entire synthesized com-
pounds against bacteria and fungus with moderate to high
antimicrobial activity. All compounds can be generalized into
a single frame work and expected to show their potency as syn-
thetic inhibitor, depending upon the structural features essen-
tial for binding in the cavity of cytochrome P450 (1ea1). All
newly synthesized molecules (3a–g) could be divided into three
segments viz. imidazole central core structure (ring A),
characteristics substituted pyrimidine nucleus (ring B) and
two phenyl rings (rings C and D). Our hybrid molecule consid-
ered as a template scaffold in which one can insert substituted
aromatic ring as a substituent of ring B to enhance the speci-
ﬁcity towards microorganism as antifungal activities. These
hybrid molecules possesses ring A as imidazole subunit, ring
B constitute substituted pyrimidine ring at C-2 position of
imidazole ring while the attached two phenyl ring at C-4 and
C-5 position of main imidazole moiety raised antifungal activ-
ity (Fig. 8).
Figure 7 Docked in the active site of cytochrome P450 3c.
Table 5 Antimicrobial-screening results of synthesized compounds 3a–g.
Entry S. aureus (mm) S. typhi (mm) P. aurogenosa (mm) K. Pneumonae (mm) C. albicans (mm)
3a 10 9.0 9.0 12.0 9.0
3b 10 12 – 12.0 12.0
3c 9.0 9.0 12.0 10.0 13.0
3d 12.0 – 10.0 15.0 –
3e 6.0 13.0 12.0 9.0 –
3f 6.0 11.0 6.0 18.0 12.0
3g 7.0 13.0 10.0 8.0 9.0
N 10.0 11.0 22.0 24.0 –
G – – – – 11.0
N, Norﬂoxacin; G, Griesofulvin.
Figure 8 Structure–activity relationship.
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It is interesting to note that the compounds 3b, 3c and 3f
exhibit signiﬁcant antifungal activity revealing that the pres-
ence of electron withdrawing groups like –Cl, NO2 as substitu-
ent at different position on aromatic ring attached to ring B
improved the efﬁcacy of the compounds. The two phenyl rings
are essential for modulation of the hydrophobic interaction
which enhanced its antifungal activity. Other compounds,
exhibited moderate activity against fungi and bacteria due to
the presence of –OCH3 and –OH group on substituted aro-
matic ring.
4. Conclusion
We report herein, facile synthesis of several biologically active
imidazolylpyrimidine derivatives under solvent free condition
and none conventionally, docking studies and experimental
observation suggest that they could constitute the unique class
of 1eal inhibitor. Diversity of substitution on the skeleton of
pyrimidine scaffold leads to signiﬁcantly modulated selectivity
in the 1eal active site cavity. Substituted p-chloro phenyl ring
at C-4 position of pyrimidine or attached to C-2 carbon of
imidazole ring enhances the binding capacity and selectivity
and results in enhanced discrimination with cytochrome
P450demethylase CPY 51 active site. A joint molecule of imi-
dazolylpyrimidine improves speciﬁcity and efﬁcacy of both nu-
clei against microorganism. The dry media reaction proceeded
rapidly in a forward direction and time required for comple-
tion was highly reduced from hours to minutes. The negative
bonding score, relatively short and easy synthesis of these mol-
ecules make them attractive candidates for further exploration.
Further computation evaluation was validated by experimen-
tal study through ecofriendly method without using toxic
solvent.
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Crystallographic data for the structural analysis reported in
this paper have been deposited with the Cambridge Crystallo-
graphic Data Centre as CCDC 687592. Copies of the informa-
tion may be obtained free of charge from Director, CCDC, 12,
Union Road, CambridgeCBZ1EZ, UK. (Fax: +44 1223
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www.ccdc.cam.ac.uk).
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